Skip Navigation


Nucleic Acids Research Advance Access originally published online on November 16, 2008
Nucleic Acids Research 2009 37(1):70-77; doi:10.1093/nar/gkn904
This Article
Right arrow Full Text Freely available
Right arrow Print PDF (2510K) Freely available
Right arrow Screen PDF (515K) Freely available
Right arrow Supplementary Data
Right arrowOA All Versions of this Article:
37/1/70    most recent
gkn904v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Commercial Re-use Guidelines
for Open Access NAR Content
Google Scholar
Right arrow Articles by Davis, S.
Right arrow Articles by Esau, C.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Davis, S.
Right arrow Articles by Esau, C.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Nucleic Acids Research, 2009, Vol. 37, No. 1 70-77
© 2008 The Author(s)
This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/2.0/uk/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

RNA

Potent inhibition of microRNA in vivo without degradation

Scott Davis1, Stephanie Propp2, Susan M. Freier2, Laura E. Jones3, Martin J. Serra3, Garth Kinberger2, Balkrishen Bhat1, Eric E. Swayze2, C. Frank Bennett2 and Christine Esau1,*

1Regulus Therapeutics, 2Isis Pharmaceuticals, Carlsbad, CA 92008 and 3Allegheny College, Meadville, PA 16335, USA

*To whom correspondence should be addressed. Tel: +1 760 268 6842; Fax: +1 760 268 6802; Email: cesau{at}regulusrx.com

Received July 30, 2008. Revised October 24, 2008. Accepted October 28, 2008.

Chemically modified antisense oligonucleotides (ASOs) are widely used as a tool to functionalize microRNAs (miRNAs). Reduction of miRNA level after ASO inhibition is commonly reported to show efficacy. Whether this is the most relevant endpoint for measuring miRNA inhibition has not been adequately addressed in the field although it has important implications for evaluating miRNA targeting studies. Using a novel approach to quantitate miRNA levels in the presence of excess ASO, we have discovered that the outcome of miRNA inhibition can vary depending on the chemical modification of the ASO. Although some miRNA inhibitors cause a decrease in mature miRNA levels, we have identified a novel 2'-fluoro/2'-methoxyethyl modified ASO motif with dramatically improved in vivo potency which does not. These studies show there are multiple mechanisms of miRNA inhibition by ASOs and that evaluation of secondary endpoints is crucial for interpreting miRNA inhibition studies.


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 Proc. Natl. Acad. Sci. USAHome page
E. McGlinn, S. Yekta, J. H. Mansfield, J. Soutschek, D. P. Bartel, and C. J. Tabin
In ovo application of antagomiRs indicates a role for miR-196 in patterning the chick axial skeleton through Hox gene regulation
PNAS, November 3, 2009; 106(44): 18610 - 18615.
[Abstract] [Full Text] [PDF]

Home page
 Hum Mol GenetHome page
M. S. Weinberg and M. J.A. Wood
Short non-coding RNA biology and neurodegenerative disorders: novel disease targets and therapeutics
Hum. Mol. Genet., April 15, 2009; 18(R1): R27 - R39.
[Abstract] [Full Text] [PDF]


Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.